Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
MinuteCE®
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
CME/CE Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
1.00 credit
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Project Oncology®
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Lajos Pusztai, MD, DPhil
- Lajos Pusztai, MD, DPhil
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD; Mohamed Abdelbaki, MD
- Shelina Ramnarine, PhD
- Mohamed Abdelbaki, MD
MinuteCE®
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 credits 4 episodes
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 credits 4 episodes
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits

Medical News

Medical News
Severe Malnutrition Predicts Worse Survival in Lung Cancer
08/28/2026
Read more
Medical News
Survival Improvements in Recurrent and Metastatic ESCC Cohort
08/28/2026
Read more
Medical News
Metabolic Syndrome Raises Mortality Risk in Breast Cancer Survivors
08/28/2026
Read more
Medical News
ROI Dilation Disrupts Pediatric Brain Tumor ADC Radiomics
08/24/2026
Read more

CME/CE

Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
0.75 program credits
- Saad Z. Usmani, MD, MBA
0.75 program credits
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CE
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS; Ghayas Issa, MD
0.50 credits
- Amer Zeidan, MBBS
- Ghayas Issa, MD
0.50 credits

Clinical Practice

Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CE
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
1.00 credit
- Sagar Lonial, MD, FACP
1.00 credit
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits

Programs

3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
0.75 program credits
- Saad Z. Usmani, MD, MBA
0.75 program credits
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Project Oncology®
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Project Oncology®
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD; John Mascarenhas, MD
- Shelina Ramnarine, PhD
- John Mascarenhas, MD
- Marina Kremyanskaya, MD